Taiko Pharmaceutical Co (TSE:4574) EBIT per Share: 円-1.55 (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4574 Taiko Pharmaceutical Co Ltd TSE:4574
64 GF Score
Price 円276.00
GF Value 円352.09
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Taiko Pharmaceutical Co EBIT per Share?

Taiko Pharmaceutical Co TSE:4574 +3.37% 64 EBIT per Share is 円-1.55 as of Dec. 2025. GuruFocus rates TSE:4574 with a GF Score™ of 64/100 and a GF Value™ of 円352.09 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 811 Drug Manufacturers companies, Taiko Pharmaceutical Co ranks worse than 123304.44% on this metric.

Taiko Pharmaceutical Co's EBIT per Share for the three months ended in Dec. 2025 was 円0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was 円-1.55.

During the past 12 months, the average EBIT per Share Growth Rate of Taiko Pharmaceutical Co was -27.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Taiko Pharmaceutical Co's EBIT per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Taiko Pharmaceutical Co was 70.80% per year. The lowest was -43.00% per year. And the median was -3.30% per year.

TSE:4574's 3-Year EBIT Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.5
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Taiko Pharmaceutical Co's EBIT for the three months ended in Dec. 2025 was 円0 Mil.

Taiko Pharmaceutical Co  (TSE:4574) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Taiko Pharmaceutical Co EBIT per Share Related Terms

Taiko Pharmaceutical Co EBIT per Share Historical Data

* Premium members only.

The historical data trend for Taiko Pharmaceutical Co's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiko Pharmaceutical Co EBIT per Share Chart

Taiko Pharmaceutical Co Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -204.12 -111.44 -75.06 11.42 19.17

Taiko Pharmaceutical Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.37 0.32 0.00 0.00 -1.87
TSE:4574
64GF Score
Taiko Pharmaceutical Co Ltd TSE:4574
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taiko Pharmaceutical Co EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Taiko Pharmaceutical Co's EBIT per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBIT per Share(A: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=963/50.236
=19.17

Taiko Pharmaceutical Co's EBIT per Share for the quarter that ended in Dec. 2025 is calculated as

EBIT per Share(Q: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=0/50.236
=0.00

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-1.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of 円-1.55 mean?
Taiko Pharmaceutical Co (TSE:4574) has a EBIT per Share of 円-1.55 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Taiko Pharmaceutical Co and its competitors. According to the industry distribution chart, Taiko Pharmaceutical Co ranks #999999 out of 811 companies in the Drug Manufacturers industry.
Is Taiko Pharmaceutical Co's EBIT per Share too high?
Taiko Pharmaceutical Co's current EBIT per Share is 円-1.55. Based on the distribution chart, Taiko Pharmaceutical Co ranks #999999 out of 811 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Taiko Pharmaceutical Co has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Taiko Pharmaceutical Co's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Taiko Pharmaceutical Co ranks #999999 out of 811 companies for EBIT per Share. This places Taiko Pharmaceutical Co in the lower half of its industry. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Taiko Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiko Pharmaceutical Co's current EBIT per Share is 円-1.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiko Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Taiko Pharmaceutical Co (TSE:4574) is currently considered Modestly Undervalued. The stock's GF Value™ is 円352.09, compared to a current price of 円276.00 — trading 21.6% below its estimated fair value. The current EBIT per Share is 円-1.55. Taiko Pharmaceutical Co's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Taiko Pharmaceutical Co (TSE:4574), the current EBIT per Share is 円-1.55 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Taiko Pharmaceutical Co (TSE:4574) Overvalued in 2026?

Based on GuruFocus' analysis, Taiko Pharmaceutical Co stock appears to be undervalued. The current stock price of 円276.00 is trading 21.6% below its estimated GF Value™ of 円352.09. GuruFocus considers Taiko Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for TSE:4574:

  • EBIT per Share: 円-1.55
  • GF Value™: 円352.09 vs. price of 円276.00 (21.6% below fair value)
  • GF Score™: 64/100 with 3 warning signs

No single metric tells the full story. See the TSE:4574 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Taiko Pharmaceutical Co Business Description

Address 1-4-1 Nishihonmachi, 16th Floor, ORIX Honmachi Building, Nishi-ku, Osaka, JPN, 564-0032
Taiko Pharmaceutical Co Ltd operates in three segments, namely Pharmaceutical, Infection Control, and Others. The majority of its revenue comes from Infection Control, which is into manufacturing and sales of sanitation control products, including Cleverin, Cleverin LED, and Cleverin Generator LISPASS. The pharmaceutical segment is into the manufacturing and sales of OTC medicines and designated quasi-drugs. Other business includes manufacturing and sales of wood vinegar-based products.
64GF Score

Get the complete analysis for TSE:4574

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円276.00
Price
円352.09
GF Value